Baidu
map

Br J Cancer:胰腺导管腺癌生物标志物——C4BPA

2016-09-26 Moon 译 MedSci原创

因为缺乏早期的特异性诊断标志物,胰腺导管腺癌(PDAC)仍是一种毁灭性的疾病。为了改善这种现状,研究者试图通过蛋白质组学,寻找PDAC的新型生物标志物。 通过使用串联质谱标记标签和LC-MS/MS,我们对PDAC患者术前和术后血清进行比较分析,识别PDAC的血清特异性标志物。在验证研究中,我们评估了候选蛋白质的区分能力。 对302个蛋白质进行分析后,发现了20个可能作为标志物的蛋白质,

因为缺乏早期的特异性诊断标志物,胰腺导管腺癌(PDAC)仍是一种毁灭性的疾病。为了改善这种现状,研究者试图通过蛋白质组学,寻找PDAC的新型生物标志物。

通过使用串联质谱标记标签和LC-MS/MS,我们对PDAC患者术前和术后血清进行比较分析,识别PDAC的血清特异性标志物。在验证研究中,我们评估了候选蛋白质的区分能力。

对302个蛋白质进行分析后,发现了20个可能作为标志物的蛋白质,选择C4b结合蛋白α链(C4BPA)和多聚免疫球蛋白受体(PIGR)进行进一步的研究。PDAC患者术前与术后相比,血清中C4BPA和PIGR水平更高(P<0.008、P<0.036)。

PDAC患者与健康对照组、胰腺炎患者和其他恶性肿瘤(包括胆道癌(BTC))患者相比,血清中C4BPA水平更高(P<0.001),但是对PIGR进行分析时,没有发现这种关系。

PDAC患者与非癌症患者相比较时,受试者工作曲线(ROC)下面积分别为:C4BPA 0.860;CA19-9 0.846;C4BPA+CA19-9 0.930。I和II期PDAC vs BTC,C4BPA的AUC为0.912;CA19-9的AUC为0.737。PDAC vs BTC,C4BPA的AUC为0.854;CA19-9的AUC为0.264。

我们已经证明,C4BPA是新型的、可检测早期胰腺癌的血清标志物,同时可以区分其他胃肠道肿瘤。C4BPA能否在临床上作为PDAC的有效指标,还需要将来进一步的研究。

原始出处:

Sogawa K.et al.Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.295. [Epub ahead of print]

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1943740, encodeId=b7081943e4075, content=<a href='/topic/show?id=da643638a5' target=_blank style='color:#2F92EE;'>#BPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3638, encryptionId=da643638a5, topicName=BPA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Fri Dec 23 13:38:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840924, encodeId=4fe618409240e, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jan 23 15:38:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560569, encodeId=6fe715605693c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566578, encodeId=82f715665e8b4, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135703, encodeId=47e5135e03b5, content=C4BPA也会变成肿瘤指标, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D828C4DF4609066.jpg, createdBy=280f1950963, createdName=夫夫子, createdTime=Tue Sep 27 06:52:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135566, encodeId=0291135566b3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:39 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135565, encodeId=8de113556507, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:33 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135560, encodeId=85c113556049, content=非常值得学习,要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd381919282, createdName=1e0a2178m68(暂无匿称), createdTime=Mon Sep 26 20:53:38 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
    2016-12-23 zhlpower
  2. [GetPortalCommentsPageByObjectIdResponse(id=1943740, encodeId=b7081943e4075, content=<a href='/topic/show?id=da643638a5' target=_blank style='color:#2F92EE;'>#BPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3638, encryptionId=da643638a5, topicName=BPA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Fri Dec 23 13:38:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840924, encodeId=4fe618409240e, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jan 23 15:38:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560569, encodeId=6fe715605693c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566578, encodeId=82f715665e8b4, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135703, encodeId=47e5135e03b5, content=C4BPA也会变成肿瘤指标, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D828C4DF4609066.jpg, createdBy=280f1950963, createdName=夫夫子, createdTime=Tue Sep 27 06:52:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135566, encodeId=0291135566b3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:39 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135565, encodeId=8de113556507, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:33 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135560, encodeId=85c113556049, content=非常值得学习,要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd381919282, createdName=1e0a2178m68(暂无匿称), createdTime=Mon Sep 26 20:53:38 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1943740, encodeId=b7081943e4075, content=<a href='/topic/show?id=da643638a5' target=_blank style='color:#2F92EE;'>#BPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3638, encryptionId=da643638a5, topicName=BPA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Fri Dec 23 13:38:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840924, encodeId=4fe618409240e, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jan 23 15:38:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560569, encodeId=6fe715605693c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566578, encodeId=82f715665e8b4, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135703, encodeId=47e5135e03b5, content=C4BPA也会变成肿瘤指标, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D828C4DF4609066.jpg, createdBy=280f1950963, createdName=夫夫子, createdTime=Tue Sep 27 06:52:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135566, encodeId=0291135566b3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:39 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135565, encodeId=8de113556507, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:33 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135560, encodeId=85c113556049, content=非常值得学习,要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd381919282, createdName=1e0a2178m68(暂无匿称), createdTime=Mon Sep 26 20:53:38 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1943740, encodeId=b7081943e4075, content=<a href='/topic/show?id=da643638a5' target=_blank style='color:#2F92EE;'>#BPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3638, encryptionId=da643638a5, topicName=BPA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Fri Dec 23 13:38:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840924, encodeId=4fe618409240e, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jan 23 15:38:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560569, encodeId=6fe715605693c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566578, encodeId=82f715665e8b4, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135703, encodeId=47e5135e03b5, content=C4BPA也会变成肿瘤指标, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D828C4DF4609066.jpg, createdBy=280f1950963, createdName=夫夫子, createdTime=Tue Sep 27 06:52:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135566, encodeId=0291135566b3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:39 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135565, encodeId=8de113556507, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:33 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135560, encodeId=85c113556049, content=非常值得学习,要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd381919282, createdName=1e0a2178m68(暂无匿称), createdTime=Mon Sep 26 20:53:38 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1943740, encodeId=b7081943e4075, content=<a href='/topic/show?id=da643638a5' target=_blank style='color:#2F92EE;'>#BPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3638, encryptionId=da643638a5, topicName=BPA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Fri Dec 23 13:38:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840924, encodeId=4fe618409240e, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jan 23 15:38:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560569, encodeId=6fe715605693c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566578, encodeId=82f715665e8b4, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135703, encodeId=47e5135e03b5, content=C4BPA也会变成肿瘤指标, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D828C4DF4609066.jpg, createdBy=280f1950963, createdName=夫夫子, createdTime=Tue Sep 27 06:52:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135566, encodeId=0291135566b3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:39 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135565, encodeId=8de113556507, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:33 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135560, encodeId=85c113556049, content=非常值得学习,要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd381919282, createdName=1e0a2178m68(暂无匿称), createdTime=Mon Sep 26 20:53:38 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
    2016-09-27 夫夫子

    C4BPA也会变成肿瘤指标

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1943740, encodeId=b7081943e4075, content=<a href='/topic/show?id=da643638a5' target=_blank style='color:#2F92EE;'>#BPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3638, encryptionId=da643638a5, topicName=BPA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Fri Dec 23 13:38:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840924, encodeId=4fe618409240e, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jan 23 15:38:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560569, encodeId=6fe715605693c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566578, encodeId=82f715665e8b4, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135703, encodeId=47e5135e03b5, content=C4BPA也会变成肿瘤指标, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D828C4DF4609066.jpg, createdBy=280f1950963, createdName=夫夫子, createdTime=Tue Sep 27 06:52:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135566, encodeId=0291135566b3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:39 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135565, encodeId=8de113556507, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:33 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135560, encodeId=85c113556049, content=非常值得学习,要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd381919282, createdName=1e0a2178m68(暂无匿称), createdTime=Mon Sep 26 20:53:38 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
    2016-09-26 知难而进

    继续关注!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1943740, encodeId=b7081943e4075, content=<a href='/topic/show?id=da643638a5' target=_blank style='color:#2F92EE;'>#BPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3638, encryptionId=da643638a5, topicName=BPA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Fri Dec 23 13:38:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840924, encodeId=4fe618409240e, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jan 23 15:38:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560569, encodeId=6fe715605693c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566578, encodeId=82f715665e8b4, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135703, encodeId=47e5135e03b5, content=C4BPA也会变成肿瘤指标, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D828C4DF4609066.jpg, createdBy=280f1950963, createdName=夫夫子, createdTime=Tue Sep 27 06:52:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135566, encodeId=0291135566b3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:39 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135565, encodeId=8de113556507, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:33 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135560, encodeId=85c113556049, content=非常值得学习,要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd381919282, createdName=1e0a2178m68(暂无匿称), createdTime=Mon Sep 26 20:53:38 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
    2016-09-26 知难而进

    谢谢分享!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1943740, encodeId=b7081943e4075, content=<a href='/topic/show?id=da643638a5' target=_blank style='color:#2F92EE;'>#BPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3638, encryptionId=da643638a5, topicName=BPA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c838337, createdName=zhlpower, createdTime=Fri Dec 23 13:38:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840924, encodeId=4fe618409240e, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jan 23 15:38:00 CST 2017, time=2017-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560569, encodeId=6fe715605693c, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566578, encodeId=82f715665e8b4, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Sep 28 08:38:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135703, encodeId=47e5135e03b5, content=C4BPA也会变成肿瘤指标, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D828C4DF4609066.jpg, createdBy=280f1950963, createdName=夫夫子, createdTime=Tue Sep 27 06:52:18 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135566, encodeId=0291135566b3, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:39 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135565, encodeId=8de113556507, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Mon Sep 26 20:55:33 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135560, encodeId=85c113556049, content=非常值得学习,要重视, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd381919282, createdName=1e0a2178m68(暂无匿称), createdTime=Mon Sep 26 20:53:38 CST 2016, time=2016-09-26, status=1, ipAttribution=)]
    2016-09-26 1e0a2178m68(暂无匿称)

    非常值得学习,要重视

    0

相关资讯

Annal Onco:西妥昔单抗/吉西他滨/调强放疗(IMRT)新辅助化放疗治胰腺导管腺癌有效

     《肿瘤学年鉴》(Annals of Oncology)近期发表的一项研究表明,西妥昔单抗/吉西他滨/调强放疗(IMRT)新辅助化疗对胰腺导管腺癌(PDAC)有疗效。   新辅助方案包括西妥昔单抗负荷剂量400 mg/m2,继以西妥昔单抗250 mg/m2/周和吉西他滨50 mg/m2每周2次,同步IMRT 54 G

Ann Surg:胃亚型胰腺导管内乳头状黏液瘤常恶变为胰腺导管腺癌

在2013年3月25日在线出版的《外科学年鉴》(Annals of Surgery)杂志上,发表了美国外科医师学会会员、日本九州大学Masao Tanaka博士等人的一项研究结果,该研究通过组织病理学方法进行亚型确定,旨在鉴定出胰腺导管腺癌(PDAC)的高风险患者组别,PDAC可独立出现于存在胰腺导管内乳头状黏液瘤(IPMN)的胰腺之中。目前在IPMN与PDAC的不同病理特征,包括IPMN组织病理

Am J Gastroenterol:二甲双胍还可以治疗胰腺癌?

目的:胰腺导管腺癌(PDAC)仍然是一个非常致命的疾病。糖尿病(DM)既是PDAC的危险因素和也是其后遗症。二甲双胍是治疗II型糖尿病的双胍类口服降糖药。研究目的是探究PDAC诊断前,使用二甲双胍治疗DM患者,二甲双胍能否改善PDAC的生存。校正混杂因素如糖尿病的严重程度等。方法:通过SEER相关数据库识别2007-2011年诊断为PDAC的患者,糖尿病疾病严重程度指数(DCSI)评估DM病情严重

PEAK1 可能是胰腺导管腺癌早期生物学标志物

  美国的研究人员在新一期《癌症研究》(Cancer Res, 2012 72; 2554 )杂志上报告说,一种名为PEAK1 的酪氨酸激酶可能是胰腺导管腺癌的早期生物学标志物,这一发现有助于将来开发针对这一致命性癌症的新疗法。   据美国全国癌症研究所公布的数据,胰腺导管腺癌是全美第四大癌症死因。由于胰腺肿瘤生长过程中没有明显症状,很多患者检查出患病时已处晚期。5年生存率只有3%-5

CCR:微RNA表达异常降低胰腺导管腺癌(PDAC)患者生存率

 《临床癌症研究》杂志11月23日在线发表的一项研究表明,胰腺导管腺癌(PDAC)组织微RNA(miR)的表达显著改变。一些miR的异常表达,包括miR-21过度表达和miR-34a表达不足与患者生存率下降独立相关。   该研究分析了48例胰腺导管腺癌组织中miR表达情况,评估了其与肿瘤分期、淋巴结状态和复发部位的关联,并在另外24例患者中,验证了经挑选的可能的具有预后意义的miR。   结果

Baidu
map
Baidu
map
Baidu
map